再鼎医药(09688.HK) 公布第一季度业绩,按美国公认会计准则,总收入1.06亿美元,按年增加22.2%。亏损净额由上年同期5,347万美元,收窄至4,844万美元,主要是产品收入的增长快于运营开支;每股亏损4美仙。
公布日期 | 派息事项 | 派息内容 |
---|---|---|
2025/02/27 | 末期业绩 | 无派息 |
2024/11/12 | 第三季业绩 | 无派息 |
2024/08/07 | 中期业绩 | 无派息 |
2024/05/09 | 第一季业绩 | 无派息 |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.